RU2002108346A - PHARMACEUTICAL COMPOSITION - Google Patents
PHARMACEUTICAL COMPOSITION Download PDFInfo
- Publication number
- RU2002108346A RU2002108346A RU2002108346/14A RU2002108346A RU2002108346A RU 2002108346 A RU2002108346 A RU 2002108346A RU 2002108346/14 A RU2002108346/14 A RU 2002108346/14A RU 2002108346 A RU2002108346 A RU 2002108346A RU 2002108346 A RU2002108346 A RU 2002108346A
- Authority
- RU
- Russia
- Prior art keywords
- group
- hydrogen atom
- halogen
- alkyl
- lower alkyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 457
- 125000000217 alkyl group Chemical group 0.000 claims 438
- 229910052717 sulfur Inorganic materials 0.000 claims 183
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 182
- 229910052736 halogen Inorganic materials 0.000 claims 169
- 229910052760 oxygen Inorganic materials 0.000 claims 166
- 229910052757 nitrogen Inorganic materials 0.000 claims 156
- 150000002367 halogens Chemical class 0.000 claims 143
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 143
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 117
- 125000005842 heteroatom Chemical group 0.000 claims 117
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 112
- 125000005843 halogen group Chemical group 0.000 claims 104
- 125000003545 alkoxy group Chemical group 0.000 claims 91
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 90
- 150000001875 compounds Chemical class 0.000 claims 81
- 125000003277 amino group Chemical group 0.000 claims 78
- 150000003839 salts Chemical class 0.000 claims 70
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 65
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 65
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 65
- 125000004432 carbon atom Chemical group C* 0.000 claims 53
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 52
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 52
- 229910052799 carbon Inorganic materials 0.000 claims 52
- 125000004093 cyano group Chemical group *C#N 0.000 claims 52
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 52
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 52
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 39
- -1 phenylsulfonylamino group Chemical group 0.000 claims 39
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 26
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 26
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 26
- 125000001624 naphthyl group Chemical group 0.000 claims 26
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 13
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
- 125000002252 acyl group Chemical group 0.000 claims 13
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 13
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 13
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 125000001041 indolyl group Chemical group 0.000 claims 13
- 125000004043 oxo group Chemical group O=* 0.000 claims 13
- 206010012601 diabetes mellitus Diseases 0.000 claims 9
- 206010020772 Hypertension Diseases 0.000 claims 7
- 229940122355 Insulin sensitizer Drugs 0.000 claims 7
- 208000002249 Diabetes Complications Diseases 0.000 claims 6
- 206010012655 Diabetic complications Diseases 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 201000009925 nephrosclerosis Diseases 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 4
- 206010020710 Hyperphagia Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 4
- 206010033645 Pancreatitis Diseases 0.000 claims 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 4
- 208000004104 gestational diabetes Diseases 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 4
- 201000008980 hyperinsulinism Diseases 0.000 claims 4
- 235000020824 obesity Nutrition 0.000 claims 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 230000004584 weight gain Effects 0.000 claims 4
- 235000019786 weight gain Nutrition 0.000 claims 4
- 208000004611 Abdominal Obesity Diseases 0.000 claims 3
- 206010002383 Angina Pectoris Diseases 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 206010011878 Deafness Diseases 0.000 claims 3
- 206010012665 Diabetic gangrene Diseases 0.000 claims 3
- 206010012669 Diabetic hyperosmolar coma Diseases 0.000 claims 3
- 206010054805 Macroangiopathy Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 208000017442 Retinal disease Diseases 0.000 claims 3
- 206010038923 Retinopathy Diseases 0.000 claims 3
- 208000005946 Xerostomia Diseases 0.000 claims 3
- 230000037213 diet Effects 0.000 claims 3
- 235000005911 diet Nutrition 0.000 claims 3
- 206010013781 dry mouth Diseases 0.000 claims 3
- 206010061989 glomerulosclerosis Diseases 0.000 claims 3
- 230000010370 hearing loss Effects 0.000 claims 3
- 231100000888 hearing loss Toxicity 0.000 claims 3
- 208000016354 hearing loss disease Diseases 0.000 claims 3
- 230000001631 hypertensive effect Effects 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 201000001119 neuropathy Diseases 0.000 claims 3
- 230000007823 neuropathy Effects 0.000 claims 3
- 230000003836 peripheral circulation Effects 0.000 claims 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims 3
- 230000000391 smoking effect Effects 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 208000019553 vascular disease Diseases 0.000 claims 3
- FHEYFIGWYQJVDR-ACJLOTCBSA-N 2-[[3-[(2r)-2-[[(2r)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1h-indol-7-yl]oxy]acetic acid Chemical compound C1([C@@H](O)CN[C@@H](CC=2C3=CC=CC(OCC(O)=O)=C3NC=2)C)=CC=CC(Cl)=C1 FHEYFIGWYQJVDR-ACJLOTCBSA-N 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229960005095 pioglitazone Drugs 0.000 claims 2
- 229960004586 rosiglitazone Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 231100000489 sensitizer Toxicity 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 0 Cc1cc(C2(*)*(*)C2)ccc1 Chemical compound Cc1cc(C2(*)*(*)C2)ccc1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (24)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11/250443 | 1999-09-03 | ||
| JP25044399 | 1999-09-03 | ||
| JP2000056021 | 2000-02-28 | ||
| JP2000/56021 | 2000-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2002108346A true RU2002108346A (en) | 2003-11-20 |
Family
ID=26539777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002108346/14A RU2002108346A (en) | 1999-09-03 | 2000-09-01 | PHARMACEUTICAL COMPOSITION |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1212090A2 (en) |
| KR (1) | KR20020063555A (en) |
| CN (1) | CN1372476A (en) |
| AR (1) | AR031674A1 (en) |
| AU (1) | AU6868000A (en) |
| CA (1) | CA2383946A1 (en) |
| CO (1) | CO5180632A1 (en) |
| HK (1) | HK1044711A1 (en) |
| HU (1) | HUP0203285A3 (en) |
| NO (1) | NO20021036L (en) |
| PE (1) | PE20010580A1 (en) |
| PL (1) | PL354295A1 (en) |
| RU (1) | RU2002108346A (en) |
| WO (1) | WO2001017513A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1695716A2 (en) * | 2000-12-26 | 2006-08-30 | Sankyo Company, Limited | Medicinal compositions containing diuretics and insulin sensitizers |
| DE60233655D1 (en) | 2001-04-04 | 2009-10-22 | Ortho Mcneil Janssen Pharm | R AND RETINOID X RECEPTOR MODULATORS |
| ES2321815T3 (en) | 2001-04-04 | 2009-06-12 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | THERAPEUTIC COMBINATION THAT INCLUDES REABSORTION AND GLUCOSE INHIBITORS AND PPAR MODULATORS. |
| FR2838968A1 (en) * | 2002-04-30 | 2003-10-31 | Lipha | ASSOCIATION OF INSULIN AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR TREATING DIABETES |
| WO2003106418A1 (en) * | 2002-06-01 | 2003-12-24 | 住友製薬株式会社 | Indole, indazole, and benzazole derivative |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4649189A (en) * | 1988-11-14 | 1990-06-12 | Upjohn Company, The | Alpha-amino-indole-3-acetic acids useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents |
| ES2059121T5 (en) * | 1990-02-09 | 2000-12-01 | Upjohn Co | USE OF INSULIN SENSITIZING AGENTS TO TREAT HYPERTENSION. |
| SK281865B6 (en) * | 1994-11-29 | 2001-08-06 | Dainippon Pharmaceutical Co., Ltd. | INDOLE DERIVATIVE AND ITS OPTICAL ISOMER, METHOD OF PREPARATION AND PHARMACEUTICAL PRODUCT |
-
2000
- 2000-08-29 PE PE2000000887A patent/PE20010580A1/en not_active Application Discontinuation
- 2000-08-30 AR ARP000104514A patent/AR031674A1/en not_active Application Discontinuation
- 2000-09-01 AU AU68680/00A patent/AU6868000A/en not_active Abandoned
- 2000-09-01 CO CO00065981A patent/CO5180632A1/en not_active Application Discontinuation
- 2000-09-01 HK HK02105969.4A patent/HK1044711A1/en unknown
- 2000-09-01 RU RU2002108346/14A patent/RU2002108346A/en not_active Application Discontinuation
- 2000-09-01 EP EP00956872A patent/EP1212090A2/en not_active Withdrawn
- 2000-09-01 HU HU0203285A patent/HUP0203285A3/en unknown
- 2000-09-01 CN CN00812420A patent/CN1372476A/en active Pending
- 2000-09-01 PL PL00354295A patent/PL354295A1/en not_active Application Discontinuation
- 2000-09-01 CA CA002383946A patent/CA2383946A1/en not_active Abandoned
- 2000-09-01 WO PCT/JP2000/005951 patent/WO2001017513A2/en not_active Ceased
- 2000-09-01 KR KR1020027002851A patent/KR20020063555A/en not_active Withdrawn
-
2002
- 2002-03-01 NO NO20021036A patent/NO20021036L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20021036L (en) | 2002-04-26 |
| WO2001017513A3 (en) | 2001-09-20 |
| WO2001017513A2 (en) | 2001-03-15 |
| PE20010580A1 (en) | 2001-05-25 |
| CN1372476A (en) | 2002-10-02 |
| CO5180632A1 (en) | 2002-07-30 |
| PL354295A1 (en) | 2004-01-12 |
| AR031674A1 (en) | 2003-10-01 |
| HUP0203285A2 (en) | 2003-01-28 |
| NO20021036D0 (en) | 2002-03-01 |
| KR20020063555A (en) | 2002-08-03 |
| HUP0203285A3 (en) | 2003-02-28 |
| HK1044711A1 (en) | 2002-11-01 |
| EP1212090A2 (en) | 2002-06-12 |
| AU6868000A (en) | 2001-04-10 |
| CA2383946A1 (en) | 2001-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4854511B2 (en) | Diabetes treatment | |
| US5393772A (en) | Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation | |
| RU2188013C2 (en) | Combination containing a compound of angiotensin ii-antagonistic activity | |
| AU2016204638B2 (en) | Compositions and methods of treating pulmonary hypertension | |
| US20060100195A1 (en) | Remedies for urinary frequency | |
| RU2004120781A (en) | ACETYLENE DERIVATIVES WITH ANTAGONISTIC ACTIVITY AGAINST METABOTROPIC GLUTAMATE RECEPTORS (MGIUR5) | |
| RU2007120454A (en) | Quinuclidine derivatives and their use as antagonists of M3 muscarinic receptors | |
| JP2002226401A (en) | Combination therapy for depression | |
| US20030232874A1 (en) | Methods and compositions for the treatment of chronic lymphocytic leukemia | |
| CA2287122A1 (en) | Treatment of bph with cgmp elevators | |
| JPH05509086A (en) | Treatment of chronic renal failure with imidazole angiotensin-2 receptor antagonists | |
| KR20040032141A (en) | Pharmaceutical combinations | |
| JP2005526696A5 (en) | ||
| US5719173A (en) | Method for the treatment of sclerosis of the glomeruli | |
| JP2003521516A (en) | Use of a COX-2 inhibitor as a gastric motility stimulant | |
| CN104023715A (en) | Agent for reducing adverse side effects of kinase inhibitor | |
| TW201026684A (en) | Phosphodiesterase type III (PDE III) inhibitors or Ca2+ -sensitizing agents for the treatment of hypertrophic cardiomyopathy | |
| US20030013717A1 (en) | Use of cox-2 inhibitors for constipation | |
| RU2002108346A (en) | PHARMACEUTICAL COMPOSITION | |
| RU2007106933A (en) | HSP90 INHIBITORS | |
| JPS6191124A (en) | anti-inflammatory composition | |
| US20030171393A1 (en) | Drugs for sex dysfunctions | |
| JPH10511978A (en) | Drugs for treating Alzheimer's disease | |
| JP2004504377A5 (en) | ||
| EP1307184A2 (en) | Drugs for incontinence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20050314 |